























Long-term outcome in a large cohort
ABSTRACT
Objective: To assess the long-term outcome of sleep-related hypermotor epilepsy (SHE).
Methods: We retrospectively reconstructed a representative cohort of patients diagnosed with
SHE according to international diagnostic criteria, sleep-related seizures $75% and follow-up
$5 years. Terminal remission (TR) was defined as a period of $5 consecutive years of seizure
freedom at the last follow-up. We used Kaplan-Meier estimates to calculate the cumulative time-
dependent probability of TR and to generate survival curves. Univariate and multivariate Cox
regression analyses were performed.
Results: We included 139 patients with a 16-year median follow-up (2,414 person-years). The
mean age at onset was 13 6 10 years. SHE was sporadic in 86% of cases and familial in
14%; 16% of patients had underlying brain abnormalities. Forty-five percent of patients had
at least 1 seizure in wakefulness lifetime and 55% had seizures only in sleep (typical SHE). At the
last assessment, 31 patients achieved TR (TR group, 22.3%), while 108 (NTR group, 77.7%) still
had seizures or had been in remission for ,5 years. The cumulative TR rate was 20.4%, 23.5%,
and 28.4% by 10, 20, and 30 years from inclusion. At univariate analysis, any underlying brain
disorder (any combination of intellectual disability, perinatal insult, pathologic neurologic exam-
ination, and brain structural abnormalities) and seizures in wakefulness were more frequent
among the NTR group (p 5 0.028; p 5 0.043). Absence of any underlying brain disorder (hazard
ratio 4.21, 95%confidence interval 1.26–14.05, p50.020) and typical SHE (hazard ratio 2.76,
95% confidence interval 1.31–5.85, p 5 0.008) were associated with TR.
Conclusions: Our data show a poor prognosis of SHE after a long-term follow-up. Its outcome is
primarily a function of the underlying etiology. Neurology® 2017;88:70–77
GLOSSARY
ADSHE5 autosomal dominant sleep-related hypermotor epilepsy;AED5 antiepileptic drug;CI5 confidence interval; FCD5
focal cortical dysplasia; HR 5 hazard ratio; ID 5 intellectual disability; NE 5 neurologic examination; NTR 5 not attaining
terminal remission; SF 5 seizure freedom; SHE 5 sleep-related hypermotor epilepsy; STROBE 5 Strengthening the Report-
ing of Observational Studies in Epidemiology; TR 5 terminal remission.
Sleep-related hypermotor epilepsy (SHE), previously known as nocturnal frontal lobe epilepsy
(NFLE), is a focal epilepsy characterized by hypermotor seizures occurring predominantly in
clusters during non-REM sleep. The clinical features and diagnostic criteria of SHE were
recently revised during an international consensus conference (figure e-1 at Neurology.org).1
Etiologic factors underlying SHE encompass genetic and structural causes, without signifi-
cant differences in clinical features between sporadic cases and the familial form with autosomal
dominant inheritance (ADSHE; previously autosomal dominant nocturnal frontal lobe
epilepsy).1
To date, studies addressing the long-term outcome of the whole spectrum of SHE syndrome
are lacking and the prognostic data are contradictory and are derived from noncohort studies or
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from subpopulations of patients with SHE.
ADSHE has been proposed as a paradigm of
a distinct benign focal epilepsy syndrome
occurring in patients of normal intelligence,2
despite several reports of intellectual disability
(ID)/psychiatric disorders and early-onset
refractory epilepsy associated with distinctive
mutations in the nicotinic acetylcholine recep-
tor subunit genes3 and with specific genes.4
The largest case series on sporadic SHE sug-
gested an overall drug resistance rate of 30%,
comparable to other focal epilepsies.5 The few
cohort studies available focused on the surgical
outcome of patients with refractory SHE.6,7
We aimed to assess the long-term outcome
in terms of 5-year seizure freedom (SF) rate
(terminal remission [TR]) in a large, represen-
tative cohort of consecutive patients diagnosed
with SHE according to the new shared inclu-
sion criteria.1 In addition, we analyzed clinical
predictors for TR.
METHODS This study has a cohort design and is reported fol-
lowing the STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) guidelines.8
Participants, setting, and eligibility criteria. The study was
conducted at the IRCCS Institute of Neurologic Sciences of
Bologna between September 2012 and October 2013.
An initial pool of patients with suspected SHE referred to our
institute from 1980 was reconstructed by reviewing medical and
video-polysomnographic records from the archive and the data-
bases of the epilepsy and sleep centers (figure 1).
All patients had video-EEG documentation of at least 1 sleep-
related hypermotor event. Diagnosis of SHE was based on level of
certainty according to the new diagnostic criteria (figure e-1).1
Inclusion criteria. We included patients with video-
documented (clinical) or video-EEG–documented (confirmed)
diagnosis of SHE and a follow-up of $5 years.
Because current diagnostic criteria do not specify the all-life
proportion of seizures arising from sleep with respect to wakeful-
ness,1 we labeled the frequency of sleep-related seizure according
to the following categories: (1) 100% sleep-related seizures, i.e.,
no seizures during wakefulness lifetime (these patients were
labeled as having a typical SHE pattern); (2) sleep-related seizures
.75%, i.e., the frequency of seizures during sleep largely predo-
minated seizures in wakefulness lifetime; and (3) sleep-related
seizures,75%, i.e., the proportion of seizures from sleep slightly
exceeded seizures during wakefulness; these patients were
excluded from the study.
Data collection. A medical chart recording clinical and instru-
mental updates at every control visit was reviewed for each
patient.
The last assessment was conducted by a direct visit by Octo-
ber 2013. Patients unable to attend a control visit by 1 year after
the beginning of recruitment underwent a semistructured tele-
phone interview. We focused principally on SF, ascertained as sei-
zure frequency over the preceding 5 years, by reviewing a seizure
diary. All data were collected in an ad hoc database. The e-appen-
dix provides details on database items, data collection, and
statistics.
Outcomes and prognostic factors. The primary endpoint
was TR, a period of at least 5 consecutive years without seiz-
ures at the last follow-up, regardless of treatment status.9 On
the basis of the primary end-point, we distinguished between
the TR group, made up of patients with SF for$5 years at the
last visit, and the NTR group, made up of patients not
attaining TR.
We observed 3 patterns of seizure occurrence over time:
a remitting pattern in patients who achieved TR at some point
of their disease history without any relapse, a continuous pattern
in patients having no remission at all after epilepsy onset, and an
intermittent pattern in patients in whom the epilepsy course
showed some relapsing periods. We defined relapse as the occur-
rence of any seizure after a 5-year remission had been achieved
during the epilepsy course.10
Potential prognostic factors examined are reported in table 1.
The additional variable of any underlying brain disorder was
defined as at least one of the following causative factors, possibly
in combination: ID/borderline IQ, personal history of perinatal
insult, pathologic neurologic examination (NE), and brain
abnormalities.
We referred to the International League Against Epilepsy
guidelines of drug resistance,11 ascribing the degree of pharma-
coresistance according to Perucca, 1998.12
Diagnosis was dated from either video-polysomnographic
recording of SHE seizures or diagnosis of focal epilepsy, even
if not better specified, followed by prescription of appropriate
antiepileptic drugs (AEDs). In patients whose diagnostic
Figure 1 Flow diagram of patient recruitment
SHE 5 sleep-related hypermotor epilepsy. *The final diagnosis was confirmed by 3
experts in sleep medicine and epileptology (P.T., F.P., F.B.). The final agreement required
was 100%; otherwise, cases were considered doubtful and excluded. **All cases with
video-polysomnographic (VPSG) recording of motor events of uncertain nature/not stereo-
typed (n 5 34) or for which there was no agreement among the experts (n 5 3).
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workup took .1 year (time to diagnosis .1 year), we quan-
tified the diagnostic delay.
Statistical analysis. The cumulative time-dependent probability
of conversion to a TR state was calculated by the Kaplan-Meier
estimate. The time of entry into the analysis was the date of
diagnosis of epilepsy, and the time of the endpoint was the
date of TR or the date of the last follow-up information
(truncated at 40 years of follow-up), whichever came first.
We performed univariate and multivariate Cox regression
Table 1 Descriptive statistics for the 139 patients with sleep-related hypermotor epilepsy (SHE) and univariate analysis with comparison of
the principal electroclinical features between the terminal remission (TR) and non-TR (NTR) groupsa
Total
(n 5 139), % Valid, % Missing, %
TR group
(n 5 31, 22.3%)
NTR group
(n 5 108, 77.7%) p Value
Mean age at onset, y 13.4 6 10.2 16.3 6 12.6 12.6 6 9.3 0.077
Seizures frequency at onset
Daily/multiple times daily 52 42.6 17 (12.2) 13 41.9 39 36.1 0.894
Weekly 31 25.4 7 22.6 24 22.2
Monthly 21 17.2 4 12.9 17 15.7
Yearly 15 12.3 2 6.5 13 12.0
Sporadic 3 2.5 0 0.0 3 2.8
Seizures in wakefulness 63 45.3 — 9 29.0 54 50.0 0.043b
Aura 63 45.7 1 (0.7) 13 41.9 50 46.3 0.756
Bilateral T-C seizures 46 33.8 3 (2.2) 8 25.8 38 35.2 0.465
Status epilepticus 14 10.1 1 (0.7) 1 3.2 13 12.0 0.372
Epileptiform interictal EEG 78 56.1 — 16 51.6 62 57.4 0.822
Ictal paroxysmal activity 74 53.2 — 12 38.7 62 57.4 0.047b
Pathologic NE 7 5.4 10 (7.2) 0 0.0 7 6.5 0.498
Abnormal neuroimaging 20 14.8 4 (2.9) 3 9.7 17 15.7 0.819
Any underlying brain disorder 38 24.5 11 (7.9) 3 9.7 35 32.4 0.028b
Diagnostic delay, y
0 72 53.7 5 (3.6) 11 35.4 51 49.5 0.259
1–9 7 22.6 25 24.3
>9 13 42.0 27 26.2
Personal history
FS 13 9.4 — 1 3.2 12 11.1 0.297
Perinatal insult 8 6.0 6 (4.3) 0 0.0 8 7.4 0.150
ID/borderline IQ 16 11.5 — 1 3.2 15 13.9 0.723
Developmental delay 7 5.2 4 (2.9) 1 3.2 6 5.6 0.121
Psychiatric disorders 30 24.0 14 (10.1) 5 16.1 25 23.2 0.555
OSA syndrome 12 9.2 9 (6.5) 5 16.1 7 6.5 0.199
Family history
FS 17 12.2 — 4 12.9 13 12.0 0.554
Epilepsy
Total 20 14.4 — 2 6.5 18 16.7 0.244
SHE 7 5.0 0 0.0 7 6.5 0.349
Other 6 SHE 13 9.4 2 6.5 11 10.2 0.733
Parasomnias non-REM 59 43.4 3 (2.2) 15 48.4 44 40.7 0.657
REM 23 17.0 4 (2.9) 5 16.1 18 16.7 0.748
ID 15 13.4 27 (19.4) 1 3.2 14 13.0 0.071
Psychiatric disorders 25 22.7 29 (20.9) 7 22.6 18 16.7 0.447
Abbreviations: FS 5 febrile seizures; ID 5 intellectual disability; NE 5 neurologic examination; OSA 5 obstructive sleep apnea; T-C 5 tonic-clonic.
a TR group: patients with $5 consecutive years of seizure freedom at last assessment; NTR group: patients who did not achieve TR.
bStatistically significant difference (p , 0.05).
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analyses to study the association between time to TR and
prognostic factors. The results are presented as hazard ratios
(HRs) and 95% confidence intervals (95% CIs). The
assumption of proportional hazard was assessed by Schoenfeld
residuals. Statistical analysis was performed with the Stata SE
statistical package, version 14.0.13
Standard protocol approvals, registrations, and patient
consents. The local ethics committee approved the study (10077).
RESULTS The final cohort included 139 patients
(male/female 92/47) diagnosed with video-
documented (57 patients, 41%) or video-EEG
documented (82 patients, 59%) SHE (figure 1).
The median follow-up time was 16 years (25th–
75th percentile 7–25, 2,414 person-years).
One hundred ten patients were directly assessed
between September 2012 and October 2013, while
for 29 cases (2 deceased, 27 untraceable), we consid-
ered the seizure frequency at their last clinical assess-
ment from medical records (median follow-up 11
years, 25th–75th percentile 5–23, 411 person-years,
figure e-2).
The clinical features of our population are listed
in table 1. The mean age at onset was 13.4 6 10.2
years (range 1–56 years). The median time to diag-
nosis was 11 years (range 0–58 years, 25th–75th
percentile 5–20 years). In 72 patients (53.7%, data
missing in 5), there was a diagnostic delay of
12.8 6 10.1 years (25th–75th percentile 2–59).
Although not diagnosed with SHE at onset,
another 37 patients (26.6%) received a diagnosis
of focal epilepsy or the prescription of appropriate
AEDs. Diagnostic delay was due to misdiagnosis
(34), absence of medical counseling (16), or both
(11), whereas in 11 cases, no specific causes were
identified. Parasomnias represented the main rea-
son for misdiagnosis (55.5%).
Sixty-three patients (45.3%) experienced at least
one seizure in wakefulness during their history, while
76 patients (54.7%) showed typical SHE. Differences
between the 2 groups are summarized in table e-1.
One hundred nineteen patients (85.6%) were spo-
radic cases. The remaining 20 (14.4%) reported a pos-
itive history for epilepsy within 2 degrees of
relatedness. Seven of them (5.0%) belonged to 5
ADSHE pedigrees, while 13 (9.4%) had a family his-
tory for other focal epilepsies with or without SHE.
A neuroradiologic assessment was available in all but
4 patients. Brain MRI was performed in 128 patients;
CT scan was performed in 7. Twenty-five patients with
refractory SHE underwent a presurgical assessment,
including stereo-EEGmonitoring in 12 cases (table e-2).
Twenty-two (15.8%) were lesional cases. In 20
patients, gross/multiple abnormalities or focal cere-
bral lesions were detected on imaging (table e-2).
Eight of the patients with focal lesions had MRI
and neurophysiologic findings suggestive of focal cor-
tical dysplasia (FCD) IIb, which was confirmed by
histology in 2 cases. Additionally, in 2 patients with
lesion-negative MRI who underwent surgery, FCD
I and IIb were disclosed by histology.
Seven patients (5.4%) showed pathologic NE
(table e-3). A formal neuropsychological evaluation,
available in 73 cases, disclosed a variable degree of
ID (IQ range 49–69) in 9 patients (12.3%) and bor-
derline IQ in 7 (9.6%).
Terminal remission. Of the 139 patients, 43 (31%)
were in remission at some point. Of these, 14
(10%) subsequently relapsed. The mean duration of
the longest remission period was 9.14 6 6.15 years
(median 7, range 5–28 years).
At the last assessment, 31 achieved TR (22.3%),
and the probability for TR by 10, 20, and 30 years
from inclusion was 20.4%, 23.5%, and 28.4%,
respectively. The cumulative time-dependent proba-
bility of conversion to TR is shown in figure 2. Uni-
variate association between time to TR and
prognostic factors is reported in table 1.
The mean age at TR was 33.6 6 16.75 years; the
mean disease duration was 17.46 13.46 years. At the
last follow-up, 10 patients (32.3%) were still on anti-
epileptic treatment, and 21 (67.7%) were not taking
any therapy. Among the latter, 13 (62%) withdrew
AEDs after TR, according to medical prescription
(one after surgery). Eight patients had a spontaneous
TR: 3 patients (14.3%) discontinued therapy auton-
omously before attaining seizure control, while 5 pa-
tients (23.8%) had never taken AEDs.
At the last assessment, 108 of 139 patients failed
to attain 5-year remission (NTR group 77.7%): 22
of them (20.4%) have had SF for ,5 years, and 86
(79.6%) still have seizures.
Figure 2 Terminal remission rate
The green curve representing the cumulative probability of achieving terminal remission (TR)
showed a slow trend of remission: 20.4% at 10 years from onset (97 patients at risk), 23.5%
after 20 years (59 patients at risk), and 28.4% after 30 years (24 patients at risk) and after
40 years (13 patients at risk). The gray area represents the 95% confidence interval.
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Figure e-2 shows the outcome chart with patterns
of seizure occurrence in TR and NTR patients.
Among the 86 NTR patients still with seizures, 20
(23.3%) were off medication: 5 had never started
treatment, and 15 discontinued AEDs autonomously
for ineffectiveness/severe side effects or because noc-
turnal events did not affect their quality of life. Most
of them had a milder condition (lower seizure fre-
quency, no seizures in wakefulness or bilateral
tonic-clonic seizures except in one).
The remaining 66 NTR cases (76.7%) took ade-
quate antiepileptic treatment without seizure control:
26 were on monotherapy, and 39 were taking a 2 to 5
AEDs (data not available in one). Of the 2 patients
who died, one patient with obstructive sleep apnea
comorbidity had a sudden unexpected death in epi-
lepsy after 40 years of disease,14 while the other died
of an event unrelated to epilepsy.
With the exclusion of possible factors of false drug
resistance (such as poor compliance with AEDs), the
overall rate of drug resistance was 38.8% (54 patients),
ranging from degree IIa (5 patients) to IIIb (34 patients).
Table 2 Hazard ratios for time to terminal
remission (TR) by possible prognostic
factor (univariate Cox regression
analysis)
HR for TR
(95% CI) p Value
Sex
Male 1.00
Female 1.02 (0.49–2.13) 0.95
Age at onset, y
<6 1.00
‡6 2.99 (0.89–10.02) 0.076










No 1.24 (0.61–2.52) 0.55
Bilateral T-C seizures
Yes 1.00
No 1.94 (0.90–4.19) 0.092
Status epilepticus
Yes 1.00
















No 3.82 (0.54–27.00) 0.18
ID/borderline IQ
Yes 1.00
No 2.09 (0.52–8.35) 0.30
Developmental delay
Yes 1.00




(95% CI) p Value
Psychiatric disorders
Yes 1.00













No 1.07 (0.40–2.86) 0.89
ID
Yes 1.00




Abbreviations: CI 5 confidence interval; FS 5 febrile seiz-
ures; HR 5 hazard ratio; ID 5 intellectual disability; T-C 5
tonic-clonic.
aStatistically significant difference (p value , 0.05).
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Predictors of TR. The cumulative time-dependent
probability of conversion to TR by a single
possible prognostic factor is reported in table 2.
The absence of any underlying brain disorder
(HR 4.21, 95% CI 1.26–14.05, p 5 0.020,
figure 3A) and typical SHE (HR 2.76, 95% CI
1.31–5.85, p 5 0.008, figure 3B) were associated
with TR. Age $6 years at onset showed a trend
toward TR (HR 2.99, 95% CI 0.89–10.02, p 5
0.076, figure 3C). The multivariate analysis model
including these factors did not disclose any of them
as statistically significant because they were strictly
associated with each other (data not shown).
However, their combination into one variable
with 2 categories disclosed that patients with at
least 2 of them (absence of any underlying brain
disorder, typical SHE, age at onset $6 years) had
an HR for TR of 7.38 (95% CI 1.75–31.21, p 5
0.007) compared with patients having one or none
of them (figure 3D). None of the patients with age
at onset ,6 years, with any underlying brain
disorder, and not having typical SHE reached TR.
DISCUSSION We evaluated the prognostic features
of a large, representative cohort of patients with
SHE after a long-term follow-up. Most patients
are sporadic cases of unknown etiology (70%),
but we also included patients with brain lesions
(16%) possibly associated with ID and abnormal
NE (symptomatic/remote symptomatic etiology).
Familial cases represent z14% of our cohort,
confirming that inherited genetic SHE represents
a restricted condition in the broad etiologic
spectrum of this syndrome.1,15
Our study showed that only 22.3% of patients
achieve TR after a median 16-year follow-up, most
with a remitting pattern from disease onset (figure
e-2). To date, studies on SHE prognosis have ad-
dressed overall surgical outcomes,6,7 with few reports
available on nonsurgical case series.5 This precludes
Figure 3 Terminal remission predictors
Terminal remission (TR) as a function of (A) any underlying brain disorder (at least one of the following: intellectual disability,
personal history of perinatal insult, pathologic neurologic examination, brain structural abnormalities): absence of any
underlying brain disorder (green curve) and presence of any underlying brain disorder (blue curve) identified; (B) typical
sleep-related hypermotor epilepsy (SHE; 100% of sleep-related events): patients with typical SHE (green curve) showed
a higher TR rate than patients experiencing seizures in wakefulness (blue curve); (C) age at epilepsy onset: the cumulative
probability of TR is higher in patients with age at onset $6 years (green curve) compared to patients with earlier epilepsy
onset (blue curve); (D) combined vs single TR predictors (absence of any underlying brain disorder, typical SHE, and age at
onset $6 years): the combination of at least 2 of the TR determinants identified (green curve) compared to having one or
none of them (blue curve).
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any comparison of our findings with other reports.
Despite considerable differences in the definitions of
remission, duration of follow-up, and patient selec-
tion, longitudinal cohort studies including mixed co-
horts of new-onset epilepsies consistently report
a remission rate of 65% to 85%,16,17 higher than that
in our cohort. Focal epilepsies showed TR rates only
somewhat less than that,18–24 although overall data on
the possible importance of seizure type (focal vs gen-
eralized) in remission are controversial.25 Instead, the
most important factor affecting remission appears to
be symptomatic/remote symptomatic etiology vs
nonsymptomatic etiology.25,26 Our data support this
distinction, pointing to ID, perinatal insult, patho-
logic NE, and brain abnormalities in possible associ-
ation (any underlying brain disorder) as a negative
predictor of SHE outcome.
Moreover, age at onset showed a trend toward sta-
tistical significance; the lower the age at onset, the less
likely it was for patients to enter TR. In previous stud-
ies on mixed cohorts of epilepsies, early age at onset has
been reported as both a negative23,27 and a posi-
tive19,28,29 predictor. Because early-onset refractory
SHE has been strongly associated with FCDs, partic-
ularly type IIb,7,30 the finding of early age at onset as
a possible negative predictor in our cohort could sug-
gest that an additional number of nonlesional cases
may have an underlying structural etiology. Despite
continuous improvements in MRI techniques, 15%
of FCD type II is not detected by targeted conven-
tional diagnostic imaging,31 as in 2 of our patients. The
hypothesis that symptomatic cases due to subtle FCD
are underestimated in our cohort could partly explain
the low remission rate we found. Another factor affect-
ing TR was the occurrence of seizures in wakefulness.
Our cohort showed a higher percentage of seizure in
wakefulness than other case series2 that occasionally
reported daytime seizures, especially in periods of poor
control. However, these studies did not address the
lifelong incidence of seizures in wakefulness after such
a long follow-up. In our study, comparison between
these patients and the group with 100% of sleep-
related events (typical SHE) disclosed significant
differences in terms of epileptiform abnormalities,
bilateral tonic-clonic seizures, status epilepticus, and
variables suggestive of a symptomatic etiology (table
e-1). Typical SHE resembles a milder form within
the heterogeneous spectrum of the syndrome. Interest-
ingly, patients belonging to this group also had a sig-
nificantly more frequent family history of non-REM
parasomnias, reinforcing the hypothesis of a common
underlying mechanism (dysfunction of the arousal sys-
tem) and suggesting a continuum with parasomnias.32
The NTR group encompasses a portion of patients
with mild SHE declining long-term pharmacologic
treatment because of either a poor recognition/
acceptance of the diagnosis of epilepsy or the modest
consequences of sleep-related seizures on quality of
life, driving restrictions, and social stigmatization.
We considered this a possible additional factor indi-
rectly affecting the TR rate in our cohort. These pa-
tients were not taking AEDs and consequently were
not drug resistant, which also explains why, despite
the low remission rate, the drug resistance percentage
we found (38.8%) differs little from that generally re-
ported for epilepsy.33
The low TR rate in our cohort may also be related
to the limits of a retrospective recruitment and to
other methodological reasons, in particular our strin-
gent definition of remission as 5-year SF. The ratio-
nale for this choice stemmed from evidence that
briefer remissions are nonrobust indicators of long-
term seizure outcome because many epilepsies follow
a relapsing-remitting course.10 Moreover, we defined
a relapse as the occurrence of even a single seizure
after a 5-year remission, in contrast to other studies
in which repeated seizures were necessary to define
a relapse.34 It is also possible that our cohort over-
estimates the severity of SHE because, for diagnostic
accuracy, we selected only patients with at least a hy-
permotor seizure documented on video-EEG, exclud-
ing milder cases with no seizures recorded (figure 1).
Lastly, we noted a possible referral bias because the
study was carried out in a tertiary center where pa-
tients with refractory epilepsy are assessed for presur-
gical study. However, the inclusion of patients with
milder disease referred to the sleep center of our insti-
tute allowed us to achieve a population with a consid-
erable variation in epilepsy severity. In addition, at
the last follow-up, some patients were assessed by
telephone interview to avoid the exclusion of patients
who were diagnosed and treated initially at our center
but did not return because of SF.
Our data show that SHE has a poor outcome after
a long follow-up, pointing to a symptomatic/remote
etiology as the most consistent determinant affecting
its prognosis. Lesional cases could be underestimated
in our cohort because of the limits of conventional
neuroimaging in detecting subtle FCDs, for which
surgery represents a highly effective treatment option.
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